Aims To examine the effects of sodium-glucose cotransporter-2 inhibitors (SGLT2i) on
cardiac remodelling in patients with type 2 diabetes mellitus (T2DM) and/or heart failure …

Objectives The use of sodium-glucose cotransporter-2 inhibitors (SGLT2-Is) has resulted in
significant benefits in patients with heart failure irrespective of left ventricular ejection fraction …

Background The effects of sodium-glucose cotransporter 2 inhibitors (SGLT2-Is) on recurrent
atrial fibrillation (AF) among patients undergoing catheter ablation is not well described …

Background Sodium-glucose cotransporter 2 (SGLT2) inhibitors have shown promise in
reducing the risk of atrial fibrillation (AF). However, the results are controversial and the …

Atrial fibrillation/flutter (AF/AFL) is a common cardiac arrhythmia in patients with diabetes
and is associated with an increased risk of morbidity, including ischaemic stroke and heart …

Type 2 diabetes mellitus (T2DM) is a leading risk factor for cardiovascular complications
around the globe and one of the most common medical conditions. Atrial fibrillation (AF) is …

Background Atrial fibrillation (AF) is associated with increasing risk of thromboembolic or
ischemic stroke. The CHA2DS2‐VASc score is a well‐established predictor of AF stroke …

Heart failure (HF) represents a major public health concern with increasing prevalence
among aging populations, with multifactorial pathophysiology including inflammation …

Aim To assess the effects of canagliflozin on the incidence of atrial fibrillation/atrial flutter
(AF/AFL) and other key cardiorenal outcomes in a pooled analysis of the CANVAS and …

Aims Sodium–glucose co-transporter-2 (SGLT2) inhibitors are reported to have cardiac
benefits. The effects of SGLT2 inhibitors on the prevention of atrial fibrillation (AF) remain …